WELCOME TO MEDSHADOW. WE'VE UPDATED OUR LOOK!

Quick News: Alternatives to Statins & More

Medical news: Other methods to lower cholesterol may be just as effective as statins in also reducing cardiovascular events. Researchers recently analyzed 49 trials involving more than 300,000 people that looked at different ways of lowering cholesterol. The trials were sorted into 4 groups: Those that examined statins; nonstatin treatments that work to lower LDL “bad” cholesterol levels such as diet and the drug Zetia (ezetimibe); fibrates and niacin; and the newest class of cholesterol-lowering drugs known as PCSK9 inhibitors. Statins and nonstatin interventions had similar reductions in the risk of a heart attack, stroke or need for a stent, according to the study, published in JAMA. Fibrates and niacin also worked to mitigate the risk, though the reduction was not as great as with statins and nonstatin treatments. The PCSK9 inhibitors also showed some benefit, but there have been few studies conducted to determine their long-term benefit. Published September 27, 2016. Via JAMA.

Medical news: A large percentage of FDA drug reviewers who leave the agency end up working for pharmaceutical companies, according to a new study that documents the long-suspected trend. Of 55 medical reviewers who examined applications for hematology-oncology drugs between 2001 and 2010, 15 of them — or 27% — left the agency for a career either with a biopharmaceutical company or as a consultant to one, according to the research published in The BMJ. About half of those 55 have remained at the FDA. Overall, 26 reviewers left the FDA. The findings are concerning as some critics have argued that the allure of a job in industry may unduly influence FDA staff when reviewing a drug. However, the study did not insinuate this. In addition, the study did not examine whether the reviewers worked for the drug industry prior to the FDA. Reviewers are also required to declare potential conflicts of interest. Posted September 27, 2016. Via BMJ.

Medical news: The FDA has approved a biosimilar version of the inflammatory disease treatment Humira(adalimumab) called Amjevita. The approval is only the third time the agency has approved a biosimilar — in essence, a generic version — of a biologic based drug, which can cost tens of thousands of dollars per year. In late August, the FDA approved Erelzi, the first biosimilar of an inflammatory disease treatment. Amjevita is approved to treat various conditions, including rheumatoid arthritis, psoriatic arthritis, plaque psoriasis and ankylosing spondylitis. Like Humira, Amjevita will have a “black box” warning on the increased risk of serious infections leading to hospitalization or death. Posted September 23, 2016. Via FDA.

DISCLAIMER: MedShadow provides information and resources related to medications, their effects, and potential side effects. However, it is important to note that we are not a substitute for professional medical advice, diagnosis, or treatment. The content on our site is intended for educational and informational purposes only. Individuals dealing with medical conditions or symptoms should seek guidance from a licensed healthcare professional, such as a physician or pharmacist, who can provide personalized medical advice tailored to their specific circumstances.

While we strive to ensure the accuracy and reliability of the information presented on MedShadow, we cannot guarantee its completeness or suitability for any particular individual's medical needs. Therefore, we strongly encourage users to consult with qualified healthcare professionals regarding any health-related concerns or decisions. By accessing and using MedShadow, you acknowledge and agree that the information provided on the site is not a substitute for professional medical advice and that you should always consult with a qualified healthcare provider for any medical concerns.

Was This Article Helpful?

Show Comments (0)
0 0 votes
Article Rating
Subscribe
Notify of
guest
0 Comments
Inline Feedbacks
View all comments
0
Would love your thoughts, please comment.x